A slew of recent innovations and research developments out of South Korea could greatly help senior care providers identify and monitor diseases.
The US Food and Drug Administration approved use of AI-powered sepsis detection software, SpassageQ, from SpassMed last week.
Elderly patients are not only becoming more prone to sepsis, but also subject to higher mortality rates from septic shock, researchers say.
SpassageQ also will identify anaphylaxis and hypovolemic shock.
On the same day last week, Korea’s Ministry of Food and Drug Safety approved use of a continuous glucose monitoring device from i-SENS, the CareSens Air.
The device is smaller and lighter than many other models and can be used for 15 days straight, its makers say.
Previous CareSens models won US FDA approval in 2021. Although the Mobi Health report doesn’t indicate a timeline for US availability, the company hopes the new Air model will be available in Korea by the end of the year, and in Europe in early 2024, pending clearance.
An estimated one-third of adults over the age of 65 have diabetes, according to the Endocrine Society.
The need to improve device wearability for older adults is a concern, and also can challenge caregivers, a 2022 study notes. In addition, remote patient monitoring for diabetes is an ongoing concern for both patients and providers.
Also happening in Korea, researchers from various Universities have developed an AI model for predicting the side effects of immunotherapy in cancer patients. The model uses data on patients’ genomes, transcriptomes and blood indicators to predict how severe their immunotherapy reaction may be; a preemptive assessment could avoid unnecessary fatalities.
